Citigroup
CTXR icon

Citigroup’s Citius Pharmaceuticals CTXR Stock Holding History

Citigroup’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.71K Buy
5,228
+4,385
+520% +$3.54K ﹤0.01% 5275
2025
Q4 		$655 Sell
843
-774
-48% -$968 ﹤0.01% 5572
2025
Q3 		$2K Buy
+1,617
New +$2.25K ﹤0.01% 5480
2025
Q1 		– Sell
-73
Closed -$292 – 5663
2024
Q4 		$292 Sell
73
-565
-89% -$3.81K ﹤0.01% 5650
2024
Q3 		$7.98K Sell
638
-82
-11% -$1.38K ﹤0.01% 5312
2024
Q2 		$10.5K Sell
720
-276
-28% -$4.95K ﹤0.01% 5131
2024
Q1 		$22.3K Buy
996
+288
+41% +$5.26K ﹤0.01% 4999
2023
Q4 		$13.4K Buy
708
+706
+35,300% +$13.4K ﹤0.01% 5121
2023
Q3 		$42 Sell
2
-1,462
-100% -$34.7K ﹤0.01% 5538
2023
Q2 		$43.9K Sell
1,464
-1,313
-47% -$43.2K ﹤0.01% 4713
2023
Q1 		$81.2K Buy
+2,777
New +$80.1K ﹤0.01% 4105
2022
Q3 		– Sell
-44
Closed -$1K – 5903
2022
Q2 		$1K Sell
44
-389
-90% -$10.7K ﹤0.01% 5999
2022
Q1 		$19K Sell
433
-720
-62% -$28.4K ﹤0.01% 5170
2021
Q4 		$44K Buy
1,153
+619
+116% +$28.1K ﹤0.01% 5129
2021
Q3 		$27K Buy
534
+318
+147% +$16K ﹤0.01% 5082
2021
Q2 		$19K Buy
+216
New +$13K ﹤0.01% 5321

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup's CTXR Position: Q1 2026 in Review

Citigroup increased its Citius Pharmaceuticals (CTXR) stake by 520% in Q1 2026, buying an estimated $3.54K and bringing the position to 5,228 shares worth $4.71K. The position accounts for ﹤0.01% of the portfolio, ranked #5275.

Citigroup first reported a position in CTXR in Q2 2021 and has held it in 16 quarters since. The position peaked at $81.2K in Q1 2023. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Citigroup held 5,228 shares of Citius Pharmaceuticals worth $4.71K as of Q1 2026.
  • Citigroup bought 4,385 Citius Pharmaceuticals shares in Q1 2026, an estimated $3.54K.
  • Citius Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5275 holding.
  • Citigroup first reported a position in Citius Pharmaceuticals in Q2 2021 and has held it in 16 quarters since.
  • Citigroup's Citius Pharmaceuticals position peaked at $81.2K in Q1 2023.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.